The Quantellect read.As of Nov 19, 2026, 3 active firms cover VistaGen Therapeutics Inc: 0 rate it Buy or better, 3 sit at Neutral, and 0 rate it Sell or worse, a neutral consensus. Targets are tightly clustered, $0.90 to $0.90, so the covering firms are broadly aligned. The average target of $0.90 sits 351% above the current $0.20. The rating mix has held broadly steady over recent months. On the fundamentals, the Street sees consensus EPS building from about $-0.36 next quarter toward $-1.54 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS3 active firms
Neutral
Strong Buy00%
Buy00%
Neutral3100%
Sell00%
Strong Sell00%
Based on 3 active firms as of Nov 19, 2026 (365-day activity window).
12-MONTH PRICE TARGET
$0.90
+351.1% upside
Average target across 1 active firms as of Nov 19, 2026 vs $0.20 current
Highest Target$0.90
Average Target$0.90
Lowest Target$0.90
Detailed analyst forecasts for VTGN
Showing 1–3 of 3 named analysts shown · 3 active firms in the rating projection
As of Nov 19, 2026, 0 of 3 active firms rate VTGN a Buy (3 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
VTGN EPS & revenue forecast
EPS · NEXT QUARTER
$-0.36
Range $-0.37 – $-0.35 · 2 analysts · -3% YoY
Next period, 2 analysts expect VistaGen Therapeutics Inc to earn $-0.36 a share (range $-0.37 – $-0.35), versus $-0.37 a year earlier. Full-year consensus is $-1.48, growing to $-1.54 the year after.
REVENUE · NEXT QUARTER
$250.0K
Range $0 – $500.0K · 2 analysts · -46% YoY
Revenue is expected to reach $250.0K (range $0 – $500.0K), -46.2% year-over-year. Full-year consensus is $1.7M, rising to $0 next year.
Top analysts covering VistaGen Therapeutics Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on VTGN.
#1
Jason McCarthy
Maxim Group · Rank #567
Neutral
No targeton VTGN
Overall win rate
30%
+ Follow
#2
Andrew Tsai
Jefferies
Neutral
$0.90+351.1% to target
Coverage
—
+ Follow
#3
Elemer Piros
Lucid Capital
Neutral
$1.00+401.3% to target
Coverage
—
+ Follow
#4
TL
Tim Lugo
William Blair
Neutral
No targeton VTGN
Coverage
—
+ Follow
VTGN stock forecast FAQ
What is VTGN's average 12-month price target?+
The 1 active firms with a live target average $0.90 for VistaGen Therapeutics Inc over the next 12 months, ranging from a $0.90 high to a $0.90 low, as of Nov 19, 2026.
Is VTGN stock a Buy, Sell or Neutral right now?+
The current consensus is Neutral. Of the 3 active firms as of Nov 19, 2026, 0 rate it Buy or Strong Buy, 3 rate it Neutral, and 0 rate it Sell or Strong Sell.
How many active Wall Street firms cover VTGN?+
3 active firms have a recognized rating on VistaGen Therapeutics Inc as of Nov 19, 2026, and 1 active firms carry a live 12-month price target.
Who is the most accurate analyst covering VTGN?+
Among analysts who currently cover VTGN, Jason McCarthy of Maxim Group has the strongest overall Quantellect track record (Rank #567). Their current call is Neutral.
What is VistaGen Therapeutics Inc's projected EPS for next quarter?+
The consensus estimate is $-0.36 per share (range $-0.37 – $-0.35) across 2 analysts. Full-year EPS is projected at $-1.48, rising to $-1.54 the following year.
How much revenue is VistaGen Therapeutics Inc expected to report next quarter?+
Consensus revenue is $250.0K (range $0 – $500.0K). Full-year revenue is projected at $1.7M, growing to $0 next year.
Have analysts been upgrading or downgrading VTGN lately?+
As of Nov 19, 2026, 0 of 3 active firms rate VTGN a Buy (3 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their VTGN calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.